Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Mutation prevalence tables for hereditary cancer derived from multi-gene panel testing

View ORCID ProfileSteven N. Hart, Eric C. Polley, Amal Yussuf, Siddhartha Yadav, David E. Goldgar, Chunling Hu, Holly LaDuca, Laura P. Smith, June Fujimoto, Shuwei Li, Fergus J. Couch, Jill S. Dolinsky
doi: https://doi.org/10.1101/19011981
Steven N. Hart
1Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Steven N. Hart
  • For correspondence: jdolinsky@ambrygen.com Hart.Steven@mayo.edu
Eric C. Polley
1Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amal Yussuf
4Ambry Genetics, Aliso Viejo, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Siddhartha Yadav
2Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David E. Goldgar
3Department of Dermatology, University of Utah, Salt Lake City, Utah, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chunling Hu
5Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Holly LaDuca
4Ambry Genetics, Aliso Viejo, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura P. Smith
4Ambry Genetics, Aliso Viejo, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
June Fujimoto
4Ambry Genetics, Aliso Viejo, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shuwei Li
4Ambry Genetics, Aliso Viejo, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fergus J. Couch
5Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jill S. Dolinsky
4Ambry Genetics, Aliso Viejo, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jdolinsky@ambrygen.com Hart.Steven@mayo.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Purpose Multi-gene panel testing for cancer predisposition mutations is becoming routine in clinical care. However, the gene content of panels offered by testing laboratories vary significantly, and data on mutation detection rates by gene and by panel is limited, causing confusion among clinicians on which test would be the most appropriate to order. Moreover, screening guidelines are not described in sufficient granularity to explain how differences in family, personal history, age, and other factors would affect the prevalence of finding a mutation in similar populations. The tool herein quantifies prevalence of mutations in hereditary cancer genes based on personalized clinical and demographic characteristics.

Methods Using results from approximately 150,000 multi-gene panel tests conducted at Ambry Genetics, we built an interactive prevalence tool to explore how differences in ethnicity, age of onset, and personal and family history of different cancers affect the prevalence of pathogenic mutations in 31 cancer predisposition genes, across various clinically available hereditary cancer gene panels.

Results Over 13,000 mutation carriers were identified in this high-risk population. Most of the cases were Non-Hispanic White (74%, n=109,537), but also provide an appreciable dataset for those identifying as Black (n=10,875), Ashkenazi Jewish (n=10,464), Hispanic (n=10,028), and Asian (n=7,090). The most prevalent cancer types were breast (50%), ovarian (6.6%), and colorectal (4.7%), which is expected based on genetic testing guidelines and clinician referral for testing.

Conclusion The Hereditary Cancer Multi-Gene Panel Prevalence Tool presented here can be used to provide insight into the prevalence of mutations on a per-gene and per-multigene panel basis, while conditioning on multiple custom phenotypic variables to include race and cancer type. The tool can be found at https://www.ambrygen.com/prevalence-tool.

Introduction

Between 5-10% of all cancers are associated with an inherited mutation in a cancer predisposition gene. The high rate of mutations has led to a plethora of academic researchers and genetic testing laboratories focused on defining the risk and prevalence for mutations in multiple genes and how they are associated with various cancers. In an attempt to provide some guidance into who should be tested for predisposition mutations, the National Comprehensive Cancer Network (NCCN) set out criteria to categorize individuals who are likely to contain a mutation in a predisposition gene - primarily based on an individual’s personal and family history of cancers. However, recent data has demonstrated limitations in these selection criteria for predicting who is more likely to have a positive pathogenic mutation1-3.

Historically, pre-test probability models have been the gold standard to assess the likelihood that an individual is a mutation carrier in BRCA1/2. These include BOADICEA4,5, BRCAPRO6,7, the Myriad II8,9, IBIS10, Penn II11,12, and Manchester13,14 models for breast cancers and MMRpro15 and PREMM16 for Lynch syndrome. These models, however, are limited to utility of predictions for BRCA1 and BRCA2, as they are usually the only genes accounted for in these predictions due to the relatively low frequency of pathogenic mutations in other genes, however BOADACEA now also provides a pretest probability for ATM, PALB2, and CHEK2 mutations17. These models were found to be reasonably accurate18, however, they were all derived from only a small number of cases or families which may present bias. For example, the Penn II model was derived from 169 women of whom 16% were positive for BRCA1 mutations. Manchester, BRCAPRO, and BOADICEA were developed from 1121, 2713, and 2785 probands or families, respectively, of which ∼20% had pathogenic mutations in either BRCA1 or BRCA2. The Myriad prevalence tables contain information initially derived from 10,000 consecutive cases through its clinical testing service; however the data has not been updated since 2010, and thus may no longer be representative of the population referred for hereditary cancer testing today.

While they have been incredibly useful, a key limitation to all pre-test probability models and existing prevalence tables/websites is the granularity at which they are published. For example, the Myriad tables only contain 2 populations, Ashkenazi and Non-Ashkenazi Jewish, with no information for mutation prevalence in Asian, Black or Hispanic populations. Moreover, family history information is limited to select combinations of breast and/or ovarian cancer personal and family history, even though there may also be histories of other cancers associated with hereditary cancer predisposition such as colorectal, endometrial, pancreatic, and prostate cancer. Some modeling tools can be overwhelmingly complicated or require downloading before running. If presented with insufficient numbers of exemplar data - or lack a strong statistical association for risk or outcome - then the model may not converge, failing to produce an accurate prediction. A platform providing a dynamic interface query based on substantial numbers of individuals tested in a more modern clinical setting based on multi-gene panel testing is likely to provide more precise estimations of mutation prevalence for a patient in a cohort of interest.

Simpler, interactive tools are making mutation prevalence data significantly easier to access. In 2018, Color Genomics released a website allowing quick perusal of genetic results from 50,000 individuals19. The user interface allows clinicians to estimate more refined mutation prevalence data using filtering criteria to better reflect the clinical characteristics of a given patient; however, the vast majority of tested individuals (n∼40,000) do not have a personal history of cancer, which may limit the utility of this tool.

Here, we describe the development and demonstrate the functionality of an open-access web-based tool which allows the end user to query mutation prevalence across 49 genes and 9 cancer indications with fine-grained control of demographic and clinical history factors. This tool represents data from 147,994 cases referred to Ambry Genetics for hereditary cancer testing, which is an order of magnitude larger than most of the datasets used for previous models. It also contains the largest database of underrepresented demographics referred for hereditary cancer genetic testing to include Asian, Black and Hispanic populations.

Materials and Methods

High-risk Patient Population

Study subjects included patients who underwent multigene panel testing through Ambry Genetics (Aliso Viejo, CA) between March 2012 and December 2016. Cases tested on the following panels were included: BRCAplus®, BreastNext®, CancerNext-Expanded®, CancerNext®, ColoNext®, GYNPlus®, OvaNext®, and PancNext®. Analysis of most genes on each panel consists of full gene sequencing of coding regions plus 5 base pairs into exon/intron boundaries (see Table S1.) with some exceptions3. Clinical histories were obtained from clinician-completed test requisition forms (TRFs), along with clinical documentation such as pedigrees and clinic notes, when provided. Prior research has demonstrated a high level of accuracy of such clinical information provided on TRFs compared to clinic notes and pedigrees, particularly for personal history of cancer20. Patients were asked to declare any family history of cancer, with specific categories for breast, ovarian, colorectal, pancreatic, thyroid, gastric, adrenal, prostate, and endometrial cancers. This study was deemed exempt from review by Western Institutional Review Board. Personal and family histories for breast, colorectal, melanoma, ovarian, pancreatic, prostate, thyroid, and uterine/endometrial were included if provided. Cases were grouped into one of five racial and ethnic categories based on self-report: and Non-Hispanic White, Black, Ashkenazi Jewish, Asian, or Hispanic. Only cases between 18-90 years old are included. For breast cancer, data from estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) statuses were included where available. Pathogenic mutations include variants with a classification of “pathogenic” or “likely pathogenic” based on a 5 tier variant classification scheme21.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1.

Summary age descriptions for each cancer type

View this table:
  • View inline
  • View popup
Table S1.

Panels and genes used in this study.

Interactive table application

Data were formatted into a custom R DataFrame (v. 3.3.3) object and loaded into an RShiny (v1.1.0) application. Filtering uses tidyverse (v.1.2.1), graphics with ggplot2 (v. 2.3.1). The application is located at https://www.ambrygen.com/prevalence-tool.

Results

Descriptive statistics of the cohort

Non-Hispanic Whites comprised the majority (74%) of the cohort. While breast cancer was the most prevalent cancer reported among cases (n=74,143, 50%), a large number of ovarian (n=9,768, 6.6%) and colorectal cancers (n=6,983, 4.7%) were represented as well. The median age of onset for any cancer was 56.2 years with a standard deviation of ± 13 years. Most of the patients tested were women, although 11,189 men were also tested, representing 7.4% of the total cohort.

Family History

Some level of family history was reported for 143,448 cases. Not surprisingly, the most frequent reported family history of cancers was for breast (64%), followed by colorectal (28%), prostate (20%), and ovarian (18%). Mutation carriers were most prevalent in people with a family history of breast cancer (68%), followed by colorectal (29%), prostate (21%), and ovarian (19%). Interestingly, 5.9% of cases tested reported no family history of any cancer - 11% of which were found to carry a pathogenic mutation.

Mutations

Of the 150,319 cases that underwent genetic testing, 13,401 carried pathogenic mutations-excluding heterozygous MUTYH carriers (14,475 mutations in total). Four genes were mutated in at least 1000 cases, including CHEK2 (n=2,722), BRCA2 (n=2,383) and BRCA1 (n=2,282), and ATM (n=1,272). Another 18 genes (PALB2, APC, MSH6, PMS2, BRIP1, TP53, MSH2, RAD50, MLH1, RAD51C, NBN, BARD1, CDKN2A, NF1,RAD51D, PTEN, MRE11A and CDH1) had 100-800 pathogenic mutations. Pathogenic mutations in MITF, MUTYH, FH, SMAD4, BMPR1A, FLCN, SDHB, SDHA, SDHD, STK11, EPCAM, and BAP1 were observed between 10 and 100 times. No pathogenic variants were identified in CDK4 or TSC1. Moderate risk mutations were included for APC, BRCA1, CDKN2A, CHEK2, PMS2, and TP53. In the case of MUTYH, only bi-allelic mutation carriers were considered. The c.952G>A (p.E318K) variant was the only tested variant for the MITF gene.

When comparing pathogenic mutation prevalence by gene, the overall number of mutations may be deceiving, as not all cases were tested for all genes, so we also describe mutations in the context of frequency and provide total number of cases tested on a by gene basis. Overall, CHEK2 mutations were the most prevalent (2%), followed by BRCA1, BRCA2, APC, and ATM each being found in more than 1% of tested cases. By ethnic/racial population, the Ashkenazi Jewish cases presented with mutations in 18.1% of probands followed by 17.4% in Non-Hispanic Whites, 15.2% Hispanic, 14.5% African American, and 11.8% Asian.

Exploration tool

Given the size, complexity, and value of this dataset, we built an interactive web-based tool to allow complex queries to better understand the landscape of inherited mutations in individuals at high risk for developing cancer (https://www.ambrygen.com/prevalence-tool). Users are able to select cases based on their age at first cancer diagnosis, personal history of different cancer types, family history of different cancer types, and ethnicities (Figure 1). The tool will return the prevalence of mutations for each gene, the prevalence of positive findings on nine different multi-gene panels offered through Ambry Genetics, as well as the distribution of both personal and family histories of patients after applying any of the above filtering criteria chosen by the user. As different genes are present on different panels, the number of mutations and the number of cases tested are also provided.

Figure 1.
  • Download figure
  • Open in new tab
Figure 1. Screenshot of the interactive tool.

As a demonstration of the utility of the tool, we posed the following question: “How different are mutation frequencies in the MLH1 gene from colorectal cancer cases with a family history of pancreatic cancer versus family history of prostate cancers?” To answer this question, the data were filtered for cases with a “First Cancer” of “Colorectal”, leaving the histology of those cases as “Unknown”, and then selecting the appropriate fields in the “Family History” section. Then, the number of positive mutations and the number of tested per gene are returned for all genes, including MLH1. The numbers of individuals tested and positive are returned for all genes, including MLH1, which in this case was 26/845 (3.08%) in pancreatic cancer family histories versus 22/1477 (1.76%) with a family history of prostate cancer. Feeding these values into a Fishers exact test confirm that pathogenic mutations were significantly higher in colorectal cases with a family history of pancreatic cancer (p=0.0149).

Discussion

Understanding the prevalence of pathogenic mutations in patients at high risk for inherited cancers is of utmost clinical importance as it can dramatically differ based on ethnicity, family and personal history of cancer, age of onset, and genes tested. As such, results from the Hereditary Cancer Multi-Gene Panel Prevalence Tool could help inform test panel selection for clinicians and provide more personalized pretest anticipatory guidance for patients. For example, among breast cancer patients ages 40 to 70, mutation prevalence drastically increases from 4.6% with a 5-gene panel (BRCAplus) to 10.6% when selecting a 34-gene panel (CancerNext) and then again, albeit modestly, to 11.8% when using a 67-gene panel (CancerNext-Expanded). When choosing what panel is best for a patient, clinicians must weigh the relevance of the additional genes to the patient’s phenotype and varying incremental positive yield with the addition of a higher VUS rate as more genes are tested. They can further inform their decisions by referencing the gene-specific mutation prevalence rates within the tool. In addition, mutations in some genes have been seen fewer than 10 times, despite being sequenced in over 10,000 cases (RET, GREM1, VHL, MEN1, MAX, TSC2, TMEM127, and SMARCA4), suggesting a combination of limited involvement of these genes in the cancer histories seen in the majority of this cohort and rarity of mutations in these genes. For example, SMARCA4 is associated with only a specific type of ovarian cancer, and GREM1 mutations are limited to gross deletions/duplications and specifically associated with colorectal cancer.

While the Hereditary Cancer Multi-Gene Panel Prevalence Tool was primarily designed to support clinical decision making, it could also serve as a useful resource for researchers interested in studying a specific cohort. This tool would aid investigators in the study design process by allowing them to analyze broad trends and assess feasibility based on the size of a given cohort. This tool allows the flexibility to search the parameters of interest in an appropriate cohort rather than relying only on data breakdowns that others have previously published or asking targeted questions to the owners of the cohort data. For example, the tool shows that in cases under the age of 45, who had ER-positive breast cancer as their first cancer, mutations in the CHEK2 gene are found in 4.3% of Non-Hispanic Whites compared to only 0.73% of Blacks. A researcher could assess whether the sample size by ethnicity is sufficient to address their research questions.

This tool does come with limitations. The data is based on a cohort of patients referred for hereditary cancer genetic testing due to clinical suspicion of hereditary cancer predisposition. Therefore, prevalence estimates may not be generalizable to the population at large, but rather should be viewed in the context of the clinical and family history provided within the tool. The clinical and demographic data is limited to that provided to the researchers and testing laboratory, although such a limitation is a reality in any cohort represented in a pretest probability model. In addition, while the size of the cohort contributing to this tool is orders of magnitude higher than that in most other currently available pretest probability models or tools, greater numbers of patients are still needed, particularly for ethnic minority populations, genes in which mutations are exceptionally rare, and queries for highly-specific patient characteristics.

Despite these limitations, this tool is representative of patients referred for hereditary cancer panels and is therefore highly relevant to current genetic testing practices. Continued efforts to update this tool and others like it will provide continuous benefits to patients and providers by supplying relevant information in a timely manner to support gene and panel test selection based on a patient’s personal and family history of cancer. Thanks to large scale data sharing from commercial and academic entities, it is now possible to explore complex queries that more accurately reflect the clinical experience through a simple web-based interface which draws upon data from large cohorts of patients recently referred for hereditary cancer multi-gene panel testing.

Data Availability

The website is available at https://www.ambrygen.com/clinician/resources/prevalence-tool

https://www.ambrygen.com/clinician/resources/prevalence-tool

Acknowledgements

This work was funded by the Breast Cancer Research Foundation (BCRF #16-030), NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116201], and the Mayo Clinic Center for Individualized Medicine.

References

  1. ↵
    Beitsch, P. D. et al. Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? J Clin Oncol 37, 453–460, doi:10.1200/JCO.18.01631 (2019).
    OpenUrlCrossRef
  2. Rosenthal, E. T., Bernhisel, R., Brown, K., Kidd, J. & Manley, S. Clinical testing with a panel of 25 genes associated with increased cancer risk results in a significant increase in clinically significant findings across a broad range of cancer histories. Cancer Genet 218-219, 58–68, doi:10.1016/j.cancergen.2017.09.003 (2017).
    OpenUrlCrossRef
  3. ↵
    LaDuca, H. et al. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genet Med, doi:10.1038/s41436-019-0633-8 (2019).
    OpenUrlCrossRef
  4. ↵
    Antoniou, A. C., Pharoah, P. P., Smith, P. & Easton, D. F. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 91, 1580–1590, doi:10.1038/sj.bjc.6602175 (2004).
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    Antoniou, A. C. et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98, 1457–1466, doi:10.1038/sj.bjc.6604305 (2008).
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Parmigiani, G., Berry, D. & Aguilar, O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62, 145–158, doi:10.1086/301670 (1998).
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    Biswas, S. et al. Simplifying clinical use of the genetic risk prediction model BRCAPRO. Breast Cancer Res Treat 139, 571–579, doi:10.1007/s10549-013-2564-4 (2013).
    OpenUrlCrossRef
  8. ↵
    Frank, T. S. et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16, 2417–2425, doi:10.1200/JCO.1998.16.7.2417 (1998).
    OpenUrlAbstract
  9. ↵
    Frank, T. S. et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20, 1480–1490, doi:10.1200/JCO.2002.20.6.1480 (2002).
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Tyrer, J., Duffy, S. W. & Cuzick, J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23, 1111–1130, doi:10.1002/sim.1668 (2004).
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    The Penn II Risk Model, BRCA 1 and BRCA 2 Mutation Predictor, <https://pennmodel2.pmacs.upenn.edu/penn2/> (
  12. ↵
    Couch, F. J. et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336, 1409–1415, doi:10.1056/NEJM199705153362002 (1997).
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    Evans, D. G., Lalloo, F., Wallace, A. & Rahman, N. Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. J Med Genet 42, e39, doi:10.1136/jmg.2005.031989 (2005).
    OpenUrlFREE Full Text
  14. ↵
    Evans, D. G. et al. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 41, 474–480, doi:10.1136/jmg.2003.017996 (2004).
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Chen, S. et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 296, 1479–1487, doi:10.1001/jama.296.12.1479 (2006).
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    Kastrinos, F. et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology 140, 73–81, doi:10.1053/j.gastro.2010.08.021 (2011).
    OpenUrlCrossRefPubMed
  17. ↵
    Lee, A. et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med 21, 1708–1718, doi:10.1038/s41436-018-0406-9 (2019).
    OpenUrlCrossRefPubMed
  18. ↵
    Lindor, N. M. et al. Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study. Fam Cancer 9, 495–502, doi:10.1007/s10689-010-9348-3 (2010).
    OpenUrlCrossRefPubMed
  19. ↵
    Color Data Portal, <https://data.color.com/>(
  20. ↵
    LaDuca, H. et al. Quality of Clinician-Reported Cancer History When Ordering Genetic Testing. JCO Clin Cancer Inform 2, 1–11, doi:10.1200/CCI.18.00014 (2018).
    OpenUrlCrossRefPubMed
  21. ↵
    Pesaran, T. et al. Beyond DNA: An Integrated and Functional Approach for Classifying Germline Variants in Breast Cancer Genes. Int J Breast Cancer 2016, 2469523, doi:10.1155/2016/2469523 (2016).
    OpenUrlCrossRef
Back to top
PreviousNext
Posted November 15, 2019.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Mutation prevalence tables for hereditary cancer derived from multi-gene panel testing
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Mutation prevalence tables for hereditary cancer derived from multi-gene panel testing
Steven N. Hart, Eric C. Polley, Amal Yussuf, Siddhartha Yadav, David E. Goldgar, Chunling Hu, Holly LaDuca, Laura P. Smith, June Fujimoto, Shuwei Li, Fergus J. Couch, Jill S. Dolinsky
medRxiv 19011981; doi: https://doi.org/10.1101/19011981
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Mutation prevalence tables for hereditary cancer derived from multi-gene panel testing
Steven N. Hart, Eric C. Polley, Amal Yussuf, Siddhartha Yadav, David E. Goldgar, Chunling Hu, Holly LaDuca, Laura P. Smith, June Fujimoto, Shuwei Li, Fergus J. Couch, Jill S. Dolinsky
medRxiv 19011981; doi: https://doi.org/10.1101/19011981

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (579)
  • Anesthesia (139)
  • Cardiovascular Medicine (1944)
  • Dentistry and Oral Medicine (252)
  • Dermatology (184)
  • Emergency Medicine (333)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (698)
  • Epidemiology (11100)
  • Forensic Medicine (8)
  • Gastroenterology (623)
  • Genetic and Genomic Medicine (3164)
  • Geriatric Medicine (308)
  • Health Economics (561)
  • Health Informatics (2042)
  • Health Policy (863)
  • Health Systems and Quality Improvement (782)
  • Hematology (310)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12717)
  • Intensive Care and Critical Care Medicine (707)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (334)
  • Neurology (2984)
  • Nursing (164)
  • Nutrition (463)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1550)
  • Ophthalmology (477)
  • Orthopedics (185)
  • Otolaryngology (266)
  • Pain Medicine (202)
  • Palliative Medicine (57)
  • Pathology (402)
  • Pediatrics (912)
  • Pharmacology and Therapeutics (381)
  • Primary Care Research (355)
  • Psychiatry and Clinical Psychology (2782)
  • Public and Global Health (5590)
  • Radiology and Imaging (1093)
  • Rehabilitation Medicine and Physical Therapy (632)
  • Respiratory Medicine (759)
  • Rheumatology (338)
  • Sexual and Reproductive Health (311)
  • Sports Medicine (289)
  • Surgery (343)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (132)